The patients with detectable serum OVV-01 showed a trend toward increased administration site reactions, including pain and edema at the injection site, as well as a higher incidence of fever and chest discomfort ( online supplemental table S1 ).
← all excerpts
Phase 1, open-label, multicenter, dose escalation safety and tolerability study of oncolytic virus OVV-01 in advanced solid tumors.
1
—
—